◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › IRTC

iRhythm Technologies Inc (IRTC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-08-23

iRhythm Technologies Inc (IRTC) operates in the MEDICAL DEVICES industry and is headquartered in San Francisco, United States with about 2,400 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, IRTC reported $747M in revenue and ($45M) in net income.

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.

Interactive charts & full statements → Open the IRTC valuation workbench →

IRTC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$825M	$747M	$592M	$493M	$411M	$323M	$265M	$215M	$147M	$99M	$64M	$36M	$22M	$15M
Gross Profit	$589M	$527M	$408M	$332M	$282M	$214M	$195M	$162M	$108M	$71M	$43M	$21M	$11M	$7M
Gross Margin %	71.4%	70.6%	68.9%	67.3%	68.5%	66.2%	73.5%	75.5%	73.7%	71.5%	67.4%	59.3%	51.3%	42.4%
Operating Income (EBIT)	($10M)	($37M)	($116M)	($125M)	($114M)	($100M)	($44M)	($55M)	($46M)	($28M)	($16M)	($22M)	($15M)	($11M)
Operating Margin %	-1.2%	-4.9%	-19.5%	-25.4%	-27.7%	-31.0%	-16.5%	-25.5%	-31.0%	-27.8%	-24.3%	-59.9%	-67.9%	-72.7%
Net Income	($13M)	($45M)	($113M)	($123M)	($116M)	($101M)	($44M)	($55M)	($50M)	($30M)	($21M)	($23M)	($16M)	($14M)
Net Margin %	-1.6%	-6.0%	-19.1%	-25.1%	-28.3%	-31.4%	-16.5%	-25.4%	-34.2%	-30.0%	-32.6%	-63.1%	-72.8%	-88.4%
EBITDA	$20M	($4M)	($74M)	($97M)	($92M)	($83M)	($29M)	($49M)	($45M)	($25M)	($17M)	($21M)	($15M)	($11M)
Earnings Per Share (EPS)	$-0.43	$-1.39	$-3.63	$-4.04	$-3.88	$-3.46	$-1.58	$-2.16	$-2.11	$-1.31	$-3.95	$-1.54	$-1.07	$-10.69
Shares Outstanding (M)	33M	32M	31M	31M	30M	29M	28M	25M	24M	23M	5M	15M	—	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRTC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$224M	$199M	$209M	$193M	$187M	$159M	$164M	$148M
Gross Profit	$163M	$141M	$148M	$137M	$133M	$109M	$115M	$101M
Gross Margin %	72.8%	70.9%	70.9%	71.1%	71.2%	68.8%	70.0%	68.8%
Operating Income (EBIT)	($3M)	($12M)	$9M	($4M)	($15M)	($32M)	($4M)	($50M)
Operating Margin %	-1.1%	-5.9%	4.2%	-2.1%	-7.8%	-20.3%	-2.5%	-34.1%
Net Income	$0M	($14M)	$6M	($5M)	($14M)	($31M)	($1M)	($46M)
Net Margin %	-0.2%	-7.0%	2.7%	-2.7%	-7.6%	-19.4%	-0.8%	-31.3%
EBITDA	$3M	($4M)	$16M	$5M	($5M)	($20M)	$9M	($36M)
Earnings Per Share (EPS)	$-0.01	$-0.43	$0.17	$-0.16	$-0.44	$-0.97	$-0.04	$-1.48
Shares Outstanding (M)	33M	33M	33M	32M	32M	32M	31M	31M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRTC Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$86M	$81M	$3M	($50M)	($23M)	($38M)	($14M)	($22M)	($29M)	($15M)	($17M)	($18M)	($16M)	($12M)
Capital Expenditures (CapEx)	$48M	$46M	$49M	$40M	$30M	$28M	$14M	$20M	$5M	$4M	$3M	$2M	$1M	$0M
Free Cash Flow (FCF)	$39M	$35M	($46M)	($91M)	($53M)	($66M)	($27M)	($42M)	($34M)	($18M)	($19M)	($20M)	($16M)	($12M)
FCF Margin %	4.7%	4.6%	-7.7%	-18.4%	-12.9%	-20.4%	-10.3%	-19.7%	-23.2%	-18.6%	-30.3%	-54.8%	-74.3%	-80.0%
Dividends Paid	—	—	—	—	—	$26M	$10M	—	—	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRTC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$51M	($26M)	$26M	$35M	$28M	($8M)	$19M	$24M
Capital Expenditures (CapEx)	$14M	$7M	$12M	$15M	$10M	$9M	$7M	$9M
Free Cash Flow (FCF)	$38M	($33M)	$14M	$20M	$17M	($17M)	$12M	$16M
FCF Margin %	16.7%	-16.6%	6.9%	10.4%	9.3%	-10.9%	7.5%	10.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRTC Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$1.1B	$1.0B	$931M	$433M	$448M	$463M	$512M	$306M	$120M	$133M	$138M	$38M	$19M	$13M
Cash & Cash Equivalents	$247M	$236M	$420M	$36M	$79M	$128M	$89M	$20M	$20M	$9M	$52M	$25M	$9M	$7M
Total Liabilities	$907M	$867M	$841M	$223M	$208M	$183M	$170M	$171M	$65M	$54M	$46M	$139M	$11M	$9M
Total Debt (Short + Long-Term)	$670M	$666M	$662M	$50M	$48M	$32M	$41M	$43M	$35M	$34M	$64M	$61M	$13M	$1M
Total Shareholders' Equity	$186M	$153M	$91M	$210M	$240M	$280M	$342M	$135M	$54M	$80M	$93M	($102M)	$7M	$5M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IRTC viewer.

Other Companies in MEDICAL DEVICES

BRKR · Bruker Corporation — $9 billion
HAE · Haemonetics Corporation — $5 billion
ITGR · Integer Holdings Corp — $4 billion
LIVN · LivaNova PLC — $4 billion
TMDX · TransMedics Group Inc — $3 billion
NEOG · Neogen Corporation — $3 billion
AXGN · Axogen Inc — $3 billion
ALMR · Alamar Biosciences, Inc. Common Stock — $2 billion

← IRT All “I” companies IRTR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.